StemCells, Inc. to Present at 2013 Stem Cell Meeting on the Mesa's Regen Med Partnering Forum

StemCells, Inc. to Present at 2013 Stem Cell Meeting on the Mesa's Regen Med
Partnering Forum

NEWARK, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc.
(Nasdaq:STEM), the leading stem cell company developing novel cell-based
therapeutics for disorders of the central nervous system, announced today that
President and CEO Martin McGlynn will make a presentation on the Company's
programs and operations at the Regen Med Partnering Forum during the 2013 Stem
Cell Meeting on the Mesa, to be held October 14-16. Mr. McGlynn is scheduled
to speak at 11:00 a.m. Pacific Time on Monday, October 14, at the Estancia La
Jolla Hotel in La Jolla, Calif.A live video webcast of all company
presentations will be available at: and will also be published on the
Alliance for Regenerative Medicine's (ARM) website shortly after the event.

The Stem Cell Meeting on the Mesa is a three-day conference organized by the
Sanford Consortium for Regenerative Medicine, the California Institute for
Regenerative Medicine (CIRM), and ARM.The conference brings together senior
members of the regenerative medicine industry with the scientific research
community to advance stem cell science into cures. The first two days of the
conference, October 14-15, features the Regen Med Partnering Forum, the only
partnering meeting organized specifically for the regenerative medicine and
advanced therapies industry.The conference also features a nationally
recognized Scientific Symposium, which is attended by leading scientists and
researchers and will showcase leading academic research in the field of
regenerative medicine.Please visit for
more information.

StemCells, Inc. is a sponsor of the 2013 Stem Cell Meeting on the Mesa.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization
of cell-based therapeutics and tools for use in stem cell-based research and
drug discovery. The Company's proprietary HuCNS-SC^® cells (purified human
neural stem cells) are currently in development as a potential treatment for a
broad range of central nervous system disorders.In a PhaseI clinical trial
in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in
children, the Company has shown preliminary evidence of progressive and
durable donor-derived myelination in all four patients transplanted with
HuCNS-SC cells.The Company is conducting a Phase I/II clinical trial in
chronic spinal cord injury in Switzerland, Canada and the United States, and
has reported positive interim data for the first three patients.The Company
is also conducting a Phase I/II clinical trial in dry age-related macular
degeneration (AMD) in the United States. In addition, the Company is pursuing
preclinical studies in Alzheimer's disease, with support from the California
Institute for Regenerative Medicine (CIRM).StemCells also markets stem cell
research products, including media and reagents, under the SC Proven^®
brand.Further information about StemCells is available at

Apart from statements of historical fact, the text of this press release
constitutes forward-looking statements within the meaning of the U.S.
securities laws, and is subject to the safe harbors created therein.These
statements include, but are not limited to, statements regarding the clinical
development of the Company's HuCNS-SC cells; the Company's ability to
commercialize drug discovery and drug development tools; and the future
business operations of the Company. These forward-looking statements speak
only as of the date of this news release. The Company does not undertake to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. Such statements reflect
management's current views and are based on certain assumptions that may or
may not ultimately prove valid. The Company's actual results may vary
materially from those contemplated in such forward-looking statements due to
risks and uncertainties to which the Company is subject, including those
described under the heading "Risk Factors" in the Company's Annual Report on
Form10-K for the year ended December 31, 2012 and in its subsequent reports
on Forms 10-Q and 8-K.

CONTACT: Rodney Young
         StemCells, Inc.
         Chief Financial Officer
         (510) 456-4128
         Ian Stone
         Russo Partners
         (619) 308-6541

company logo
Press spacebar to pause and continue. Press esc to stop.